About this information
Search the summaries of completed Access to Information (ATI) requests to find information about ATI requests made to the Government of Canada after January 2020. If you find a summary of interest, you can request a copy of the records at no cost using the form below each summary. Requests made through this form are considered informal requests and are not subject to the same requirements as requests under the Access to Information Act (ATIA).
If you don’t find what you are looking for you can request additional government records under an institution’s control by contacting the institution’s Access to Information and Privacy Coordinator or by submitting a formal access to information request.
*All information provided will incorporate the necessary exemptions and exclusions as per the Access to Information Act and the Privacy Act.
Download datasets of the summaries of completed access to information requests.
Found 1540 record(s)
Req # A-2023-001314
Adverse Drug Reactions (ADRs). Report numbers: E2B_06757446, E2B_06760973.Organization: Health Canada
March 2024
Req # A-2021-001082
Briefing note in the Ministerial Executive Correspondence System (MECS) for the following file: 21-106962-511, Possible Priorities for the Deputy Minister Community of Science and Technology.Organization: Health Canada
February 2024
Req # A-2022-000779
Briefing note in the Ministerial Executive Correspondence System (MECS) for the following file: 22-075262-896, Follow Up to 2019 National Indigenous Economic Development Board Progress Report Recommendations.Organization: Health Canada
February 2024
Req # A-2023-001092
Adverse Drug Reactions (ADRs). Report numbers: E2B_06622636, E2B_06621695.Organization: Health Canada
February 2024
Req # A-2023-001173
Adverse Drug Reaction (ADR). Report number: E2B_02997619.Organization: Health Canada
February 2024
Req # A-2021-001996
Briefing notes and attachments regarding the January 17, 2022 authorization of PAXLOVID TM for patients with mild to moderate COVID-19 at high risk of developing serious disease from November 1, 2021 to February 1, 2022.Organization: Health Canada
February 2024
Req # A-2022-001027
The number of prescription requests for psychedelic drugs that were made and the number of prescriptions that were authorized by Health Canada since January 5, 2022.Organization: Health Canada
February 2024
Req # A-2023-000268
Module 5.2 (Tabular Listing of all Clinical Studies) for pms-Iron Sucrose that received a Notice of Compliance on 30 July 2020. Drug Identification Number (DIN) 02502917.Organization: Health Canada
February 2024
Req # A-2023-000395
The clinical trails for the premarket approval of the Selective Serotonin Reuptake Inhibitors (SNRI) antidepressant Effexor. The table of contents for all of those 12 paper volumes.Organization: Health Canada
February 2024
Req # A-2023-000598
All notes made by the Health Canada employees who reviewed the Novavax Nuvaxovid COVID-19 vaccine, in relation to the review, that were made during the reviewal process of the drug. Date Range: January 1, 2020 to July 31, 2020.Organization: Health Canada
February 2024